kelch like family member 32Genealiases: BKLHD5 · KIAA1900 · UG0030H05 · dJ21F7.1
Q-omics provides the consensus-scored KLHL32 profile across patient tissues and cancer cell-line models. KLHL32 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLHL32 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, KLHL32 RNA expression shows 21,412 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where KLHL32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL32 survival associations across molecular data types. KLHL32 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL32 RNA expression–survival associations across cancer types. High KLHL32 expression shows favorable associations in KIRC, ACC, PAAD, LUAD, LGG and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLHL32 RNA expression.
This table summarizes KLHL32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KLHL32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL32 shows lower tumor expression in KICH, LUSC, THCA, LUAD and KIRP and higher tumor expression in COAD. The KICH box plot shows higher KLHL32 RNA expression in normal versus tumor tissue (log2 FC = −1.936, t-test p < 0.001).
This table shows molecular features associated with KLHL32 in patient tissues and cancer cell lines. In patient samples, KLHL32 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
